Form 8-K - Current report:
SEC Accession No. 0001193125-20-220386
Filing Date
2020-08-14
Accepted
2020-08-14 16:18:50
Documents
14
Period of Report
2020-08-13
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d63901d8k.htm   iXBRL 8-K 25638
2 EX-99.1 d63901dex991.htm EX-99.1 14429
6 GRAPHIC g63901g35o43.jpg GRAPHIC 4828
  Complete submission text file 0001193125-20-220386.txt   171172

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mygn-20200813.xsd EX-101.SCH 3064
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mygn-20200813_lab.xml EX-101.LAB 17374
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mygn-20200813_pre.xml EX-101.PRE 10949
7 EXTRACTED XBRL INSTANCE DOCUMENT d63901d8k_htm.xml XML 3274
Mailing Address 320 WAKARA WAY SALT LAKE CITY UT 84108
Business Address 320 WAKARA WAY SALT LAKE CITY UT 84108 801-584-3600
MYRIAD GENETICS INC (Filer) CIK: 0000899923 (see all company filings)

EIN.: 870494517 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 000-26642 | Film No.: 201105347
SIC: 2835 In Vitro & In Vivo Diagnostic Substances